What’s New in Research? - Caribbean African Regenerative Medicine

Management of Kidney Disease with Sickle Cell Disease

Main Message:

This study highlights treatments that could protect kidney health in people with sickle cell disease, a condition that disproportionately affects African, Black, and Caribbean communities. These treatments work by reducing inflammation and damage to the kidneys, offering hope to slow and treat kidney problems in these populations.

Key Points:

A subset of diabetes medications, called GLP-1 receptor agonists, may protect kidneys even in people who do not have diabetes by lowering inflammation and injury.
A new medication targeting a gene variant (APOL1), more common in people of African descent, shows promise in reducing kidney damage.
Several emerging therapies are being studied to reduce sickle cell complications and help preserve kidney function.
Managing blood pressure, anemia (low blood iron levels), and urine issues are especially important in individuals with sickle cell disease to prevent worsening kidney health.
Kidney transplant and dialysis are treatment options for kidney failure, but people with sickle cell disease often face extra challenges in accessing these care options..

Challenges & Considerations:

Because sickle cell disease mainly affects ACB populations, these groups face higher risks of kidney disease. Treatments need more research and dissemination to ensure they work well and are safe in these communities.
Careful management is needed to balance treatment benefits and side effects. There are also barriers to kidney transplant and dialysis access for these patients.

Conclusion:

Sickle cell-related kidney disease is a major health concern in ACB communities. New therapies and better care strategies offer hope to improve kidney health and quality of life. More research that focuses on these populations is essential to developing effective treatments.